Stelara patent oslo tingrett?

Stelara Patent Dispute: Oslo Tingrett

Stelara, a topical treatment for plaque psoriasis, has been at the center of a patent dispute in Norway. The Oslo Tingrett, Norway's highest court, is set to rule on the matter. But what does this dispute entail, and how does it affect patients?

Why are companies challenging this patent?

Several pharmaceutical companies have challenged the patent for Stelara, citing it as too broad and limiting. According to [${DrugPatentWatch.com}], Stelara is owned by Janssen Biotech, which has licensed the treatment from Johnson & Johnson. The patent, granted in 2013, covers the use of ustekinumab, Stelara's active ingredient, for treating plaque psoriasis.

What will this mean for patients?

If the patent is deemed invalid, it could potentially lead to cheaper generic alternatives. This could be a boon for patients who struggle to afford the high price of Stelara. However, the approval of generics may be delayed due to regulatory hurdles and the patent dispute.

How does this impact the market for psoriasis treatments?

The Stelara patent dispute has significant implications for the market. If Stelara's patent is invalidated, it could open the door for cheaper generic alternatives, potentially making treatment more accessible to patients. As a result, this could impact sales for Stelara and other psoriasis treatments.

When does exclusivity expire?

Stelara's patent is set to expire in 2023, but this could be delayed or invalidated if the dispute is resolved in favor of the challengers. The Oslo Tingrett is expected to make a ruling on the patent dispute, which could either uphold or invalidate the patent.

Sources:

1. ${DrugPatentWatch.com} https://www.drugpatentwatch.com/drug/ustekinumab